No abstract available.
Arteriovenous Fistula* ; Telangiectasia, Hereditary Hemorrhagic*

Subacute paraneoplastic myelopathy is a rare cause of myelopathy. Serepositivity for antineuronal nuclear antibodies-1(ANNA-1, Anti-Hu) is a sensitive and specific marker for the paraneoplastic syndrome with small cell lung cancer. A 57-year-old male patient was admitted because of acutely progressive paraparesis, anesthesia of both lower limbs and loss of bladder function over 3 days. He was subsequently found to have small cell lung carcinoma of limited stage. Magnetic resonance image of the thoracic spine showed signal abnormalities with mild focal enhancement in the intramedullary portion of C7-T10 segments. Concurrent CSF cytology showed no abnormal findings. He had high sero-logic titer of ANNA-1. These findings suggest of a paraneoplastic syndrome although we didn't have nectrotic patholog-ic findings. Five months after onset of neurological symptoms, he died inspite of chemotherapy and radiotherapy. We report a case of intramedullary myelopathy, probably of paraneoplastic origin, associated with small cell lung cancer.
Anesthesia ; Drug Therapy ; Humans ; Lower Extremity ; Male ; Middle Aged ; Paraneoplastic Syndromes ; Paraparesis ; Radiotherapy ; Small Cell Lung Carcinoma* ; Spinal Cord Diseases* ; Spine ; Urinary Bladder

A 24-year-old pregnant woman started to have severe hyperemesis gravidarum at 6 weeks' gestation. Six weeks later, dizziness, ataxia, visual disturbance, diplopia and confusion were developed. On admission, she presented ophthalmoplegia, nystagmus, deaeased tendon reflex, intention tremor, ataxia, confusion and memory disturbance. She was diagnosed to Wernicke-Korsakoff syndrome and 100mg of thiamine was administered intravenously daily till 28 weeks gestation and then intramuscularly. Her ocular symptns, together with neurological signs, were gradually improved. Memory disturbance slightly improved but remained at the time of delivery. The case will be presented in more details with a brief revie of literatures.
Ataxia ; Diplopia ; Dizziness ; Female ; Humans ; Hyperemesis Gravidarum* ; Korsakoff Syndrome* ; Memory ; Ophthalmoplegia ; Pregnancy ; Pregnant Women ; Reflex, Stretch ; Thiamine ; Tremor ; Young Adult

Chronic migraine (CM) is a common and disabling neurologic disorder. CM is defined as more than 15 days a month over a 3-month period, including at least 8 days per month on which their headaches and associated symptoms meet diagnostic criteria for migraine. Quality of life is highly compromised in patients with this condition, and comorbidities are more frequent than with episodic migraine. The diagnosis requires a carefully-conducted patient interview and neurologic examination, sometimes combined with additional diagnostic tests, to differentiate CM from secondary headache disorders and other primary chronic headaches. CM typically develops from episodic migraine over months to years. Several factors are associated with an increased risk of episodic migraine developing into CM, including the frequent use of abortive migraine drugs. Through identification of risk factors for progression to CM, clinicians can educate patients about modifiable risk factors and can begin appropriate individualized preventive therapy. There is a high frequency of medication overuse in CM. The first step in the management of CM complicated by medication overuse is withdrawal of the overused drugs and detoxification treatment. This article provides an overview of CM, including its epidemiology, risk factors for its development, and information on its pathophysiology, diagnosis, and management.
Comorbidity ; Diagnosis ; Diagnostic Tests, Routine ; Epidemiology ; Headache ; Headache Disorders ; Headache Disorders, Secondary ; Humans ; Migraine Disorders ; Nervous System Diseases ; Neurologic Examination ; Prescription Drug Overuse ; Quality of Life ; Risk Factors

Chronic migraine (CM) is a common and disabling neurologic disorder. CM is defined as more than 15 days a month over a 3-month period, including at least 8 days per month on which their headaches and associated symptoms meet diagnostic criteria for migraine. Quality of life is highly compromised in patients with this condition, and comorbidities are more frequent than with episodic migraine. The diagnosis requires a carefully-conducted patient interview and neurologic examination, sometimes combined with additional diagnostic tests, to differentiate CM from secondary headache disorders and other primary chronic headaches. CM typically develops from episodic migraine over months to years. Several factors are associated with an increased risk of episodic migraine developing into CM, including the frequent use of abortive migraine drugs. Through identification of risk factors for progression to CM, clinicians can educate patients about modifiable risk factors and can begin appropriate individualized preventive therapy. There is a high frequency of medication overuse in CM. The first step in the management of CM complicated by medication overuse is withdrawal of the overused drugs and detoxification treatment. This article provides an overview of CM, including its epidemiology, risk factors for its development, and information on its pathophysiology, diagnosis, and management.

No abstract available.
Atrophy* ; Heat Stroke* ; Hot Temperature*

No abstract available.
Child* ; Fistula* ; Humans

No abstract available.
Headache Disorders, Primary ; Humans ; Young Adult

No abstract available.
Female ; Headache ; Humans ; Middle Aged

BACKGROUND AND PURPOSE: Chronic daily headache (CDH) is a commonly reported reason for visiting hospital neurology departments, but its prevalence, clinical characteristics, and management have not been well documented in Korea. The objective of this study was to characterize the 1-year prevalence, clinical characteristics, medical consultations, and treatment for CDH in Korea. METHODS: The Korean Headache Survey (KHS) is a nationwide descriptive survey of 1507 Korean adults aged between 19 and 69 years. The KHS investigated headache characteristics, sociodemographics, and headache-related disability using a structured interview. We used the KHS data for this study. RESULTS: The 1-year prevalence of CDH was 1.8% (95% confidence interval, 1.1-2.5%), and 25.7% of the subjects with CDH met the criteria for medication overuse. Two-thirds (66.7%) of CDH subjects were classified as having chronic migraine, and approximately half of the CDH subjects (48.1%) reported that their headaches either substantially or severely affected their quality of life. Less than half (40.7%) of the subjects with CDH reported having consulted a doctor for their headaches and 40.7% had not received treatment for their headaches during the previous year. CONCLUSIONS: The prevalence of CDH was 1.8% and medication overuse was associated with one-quarter of CDH cases in Korea. Many subjects with CDH do not seek medical consultation and do not receive appropriate treatment for their headaches.
Adult ; Epidemiology ; Headache ; Headache Disorders* ; Humans ; Korea ; Migraine Disorders ; Neurology ; Prevalence* ; Quality of Life ; Referral and Consultation